Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OD-07656,Vedolizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Affinity Asset Advisors
Deal Size : $213.0 million
Deal Type : Series D Financing
Odyssey Announces Oversubscribed $213 Million Series D Financing
Details : The proceeds will be used to advance clinical pipeline for autoimmune diseases, including OD-07656, an oral small molecule RIPK2 scaffolding inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 10, 2025
Lead Product(s) : OD-07656,Vedolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Affinity Asset Advisors
Deal Size : $213.0 million
Deal Type : Series D Financing
Lead Product(s) : OD-07656
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OD-07656 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : OD-07656
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Terray Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Odyssey And Terray Therapeutics Partner on Transcription Factor Therapies
Details : The companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across immune and inflammatory diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Terray Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Odyssey Therapeutics Announces Collaboration for AI-Driven Drug Discovery
Details : The companies will collaborate to discover & optimize small molecule medicines against select therapeutic targets by integrating artificial intelligence, machine learning & computational chemistry.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : OD-07656
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
Details : OD-07656 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Inflammatory Bowel Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : OD-07656
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Ascenta Capital
Deal Size : $101.0 million
Deal Type : Series C Financing
Odyssey Therapeutics Announces $101 Million Series C Financing
Details : The proceeds will support the advancement of multiple programs for clinical studies of immunology and oncology therapeutics & several of these molecules have the potential to enter the clinical development in next 12 months.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Ascenta Capital
Deal Size : $101.0 million
Deal Type : Series C Financing
Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing
Details : The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 13, 2022